{"id":"fosrenol-lanthanum-carbonate","safety":{"commonSideEffects":[{"rate":"15–20","effect":"Nausea"},{"rate":"10–15","effect":"Vomiting"},{"rate":"10–15","effect":"Abdominal pain"},{"rate":"5–10","effect":"Diarrhea"},{"rate":"5–10","effect":"Constipation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lanthanum is a rare earth element that acts as a phosphate binder in the GI tract. It dissociates to release lanthanum ions, which form highly insoluble lanthanum phosphate complexes with dietary phosphate. This prevents phosphate absorption and reduces serum phosphate concentrations in patients with chronic kidney disease and hyperphosphatemia.","oneSentence":"Lanthanum carbonate binds to phosphate in the gastrointestinal tract, forming insoluble complexes that are eliminated in feces, thereby reducing serum phosphate levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:24.155Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperphosphatemia in patients with chronic kidney disease on dialysis"},{"name":"Hyperphosphatemia in patients with chronic kidney disease not on dialysis"}]},"trialDetails":[{"nctId":"NCT04485039","phase":"PHASE4","title":"Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders","status":"COMPLETED","sponsor":"SIGA Technologies","startDate":"2022-06-08","conditions":"Smallpox","enrollment":44},{"nctId":"NCT03136705","phase":"PHASE1","title":"Healthy Combine Study","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-02-03","conditions":"Healthy","enrollment":39},{"nctId":"NCT01002872","phase":"NA","title":"The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Endeavor Health","startDate":"2009-10","conditions":"Metabolic Bone Disease","enrollment":19},{"nctId":"NCT02209636","phase":"PHASE4","title":"Phosphate Lowering in CKD Trial","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2014-09-15","conditions":"Chronic Kidney Disease, Cardiovascular Disease","enrollment":66},{"nctId":"NCT02258074","phase":"PHASE2","title":"The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2015-03","conditions":"Chronic Kidney Disease","enrollment":205},{"nctId":"NCT04440696","phase":"PHASE1, PHASE2","title":"To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder","status":"UNKNOWN","sponsor":"Grand Life Science (Liaoning) Co., Ltd.","startDate":"2020-10-21","conditions":"Hyperphosphatemia","enrollment":48},{"nctId":"NCT03451019","phase":"PHASE4","title":"Different Effects of Non-calcium Phosphate Binders on Serum Calcium","status":"COMPLETED","sponsor":"Medical University of Lodz","startDate":"2018-03-01","conditions":"Chronic Kidney Disease","enrollment":34},{"nctId":"NCT00557323","phase":"","title":"Long-term Effect of Lanthanum Carbonate on Bone","status":"COMPLETED","sponsor":"Shire","startDate":"2007-03-15","conditions":"Hyperphosphatemia","enrollment":34},{"nctId":"NCT00151918","phase":"PHASE3","title":"Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2005-01-07","conditions":"Kidney Failure, Chronic","enrollment":48},{"nctId":"NCT00160121","phase":"PHASE4","title":"Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2005-01-10","conditions":"Kidney Failure, Chronic","enrollment":2500},{"nctId":"NCT01130831","phase":"","title":"Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder Therapy","status":"COMPLETED","sponsor":"Shire","startDate":"2010-04-26","conditions":"End Stage Renal Disease","enrollment":66},{"nctId":"NCT00150540","phase":"PHASE3","title":"A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol.","status":"COMPLETED","sponsor":"Shire","startDate":"2002-10-14","conditions":"Kidney Failure, Chronic","enrollment":93},{"nctId":"NCT00875017","phase":"PHASE1","title":"Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2009-04-20","conditions":"Kidney Failure, Chronic","enrollment":31},{"nctId":"NCT00925704","phase":"PHASE1","title":"The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination With Fosrenol or Renvela in Healthy Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2009-06-01","conditions":"Healthy","enrollment":41},{"nctId":"NCT00441545","phase":"PHASE3","title":"Head to Head Study Against Sevelamer Hydrochloride","status":"COMPLETED","sponsor":"Shire","startDate":"2007-01-05","conditions":"Chronic Kidney Disease, Stage 5","enrollment":182},{"nctId":"NCT00880750","phase":"PHASE1","title":"Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults","status":"COMPLETED","sponsor":"Shire","startDate":"2009-01-28","conditions":"End Stage Renal Disease","enrollment":72},{"nctId":"NCT01696279","phase":"PHASE2","title":"A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis","status":"COMPLETED","sponsor":"Shire","startDate":"2013-02-15","conditions":"Chronic Kidney Disease, Hyperphosphatemia","enrollment":63},{"nctId":"NCT01128179","phase":"PHASE2","title":"Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD","status":"COMPLETED","sponsor":"Shire","startDate":"2010-12-06","conditions":"Chronic Kidney Disease","enrollment":35},{"nctId":"NCT00150566","phase":"PHASE3","title":"Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their Blood","status":"COMPLETED","sponsor":"Shire","startDate":"2004-02-09","conditions":"Kidney Failure, Chronic","enrollment":460},{"nctId":"NCT00151931","phase":"PHASE3","title":"Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving Dialysis","status":"COMPLETED","sponsor":"Shire","startDate":"2004-05-11","conditions":"Kidney Failure, Chronic","enrollment":456},{"nctId":"NCT00234702","phase":"PHASE2","title":"Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2006-01-11","conditions":"Kidney Diseases","enrollment":84},{"nctId":"NCT00452478","phase":"PHASE4","title":"Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5","status":"TERMINATED","sponsor":"Shire","startDate":"2007-05-22","conditions":"Kidney Diseases","enrollment":68},{"nctId":"NCT00567723","phase":"","title":"Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)","status":"COMPLETED","sponsor":"Shire","startDate":"2006-04-25","conditions":"Hyperphosphatemia","enrollment":2105},{"nctId":"NCT02237534","phase":"PHASE4","title":"Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia","status":"UNKNOWN","sponsor":"Osaka University","startDate":"2014-09","conditions":"Renal Insufficiency, Chronic, Hyperphosphatemia, Bone Diseases, Metabolic","enrollment":60},{"nctId":"NCT03346369","phase":"PHASE3","title":"Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2017-08-18","conditions":"Secondary Hyperoxaluria, Nephrolithiasis","enrollment":35},{"nctId":"NCT01578200","phase":"PHASE3","title":"Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2011-12-24","conditions":"Hemodialysis, Hyperphosphatemia","enrollment":2309},{"nctId":"NCT00660530","phase":"PHASE2","title":"Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2008-01","conditions":"Hyperphosphatemia, Kidney Disease","enrollment":11},{"nctId":"NCT01419327","phase":"","title":"Fosrenol Post-marketing Surveillance for Hemodialysis in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-03-23","conditions":"Hyperphosphatemia","enrollment":3267},{"nctId":"NCT00458289","phase":"PHASE1","title":"Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lanthanum Carbonate","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2007-01","conditions":"Hyperphosphatemia in Chronic Kidney Disease","enrollment":12},{"nctId":"NCT03594539","phase":"NA","title":"Phosphate Microvascular Study","status":"UNKNOWN","sponsor":"Veterans Medical Research Foundation","startDate":"2019-01-01","conditions":"End Stage Renal Disease, Hyperphosphatemia","enrollment":20},{"nctId":"NCT01955876","phase":"","title":"Fosrenol Post-marketing Surveillance in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-10-10","conditions":"Hyperphosphatemia, Kidney Disease","enrollment":343},{"nctId":"NCT01412398","phase":"","title":"Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-04-07","conditions":"Hyperphosphatemia","enrollment":446},{"nctId":"NCT01581996","phase":"NA","title":"Fosrenol and Phosphorus Balance - Lanthanum Carbonate","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2012-03","conditions":"Chronic Kidney Failure, End-stage Renal Disease, Disorders Associated With Peritoneal Dialysis","enrollment":9},{"nctId":"NCT03074058","phase":"PHASE1","title":"Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-10","conditions":"Clinical Pharmacology","enrollment":20},{"nctId":"NCT02952040","phase":"PHASE1","title":"A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-11","conditions":"Healthy Subjects","enrollment":18},{"nctId":"NCT01518387","phase":"PHASE3","title":"Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-01","conditions":"Hyperphosphatemia","enrollment":43},{"nctId":"NCT01187628","phase":"PHASE3","title":"Long-term Study in Chronic Kidney Disease (Extension From Study 14817)","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-09","conditions":"Hyperphosphatemia","enrollment":123},{"nctId":"NCT01110629","phase":"PHASE3","title":"Study in Chronic Kidney Disease (CKD) Not on Dialysis","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-06","conditions":"Hyperphosphatemia","enrollment":143},{"nctId":"NCT01053676","phase":"PHASE1","title":"Bioequivalence Study of BAY77-1931 Granule","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-01","conditions":"Hyperphosphatemia","enrollment":59},{"nctId":"NCT00767637","phase":"PHASE2","title":"Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-06","conditions":"Hyperphosphatemia, Dialysis","enrollment":14},{"nctId":"NCT01289626","phase":"PHASE1","title":"Efficacy of Lanthanum Carbonate in Calciphylaxis","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2011-02","conditions":"Calciphylaxis","enrollment":12},{"nctId":"NCT01341678","phase":"NA","title":"Circadian Rhythm Modulation by Dietary Phosphorus in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Geoffrey Block","startDate":"2011-04","conditions":"Chronic Kidney Disease","enrollment":15},{"nctId":"NCT01560884","phase":"PHASE1","title":"Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2012-04","conditions":"Safety, Phosphate Binding Capacity","enrollment":32},{"nctId":"NCT00843349","phase":"NA","title":"Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Myles Wolf","startDate":"2009-07","conditions":"Kidney Disease","enrollment":43},{"nctId":"NCT01845090","phase":"PHASE4","title":"The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23","status":"UNKNOWN","sponsor":"Camillians Saint Mary's Hospital Luodong","startDate":"2011-08","conditions":"Other Nonspecific Abnormal Serum Enzyme Levels","enrollment":30},{"nctId":"NCT00769496","phase":"PHASE2","title":"BAY 77-1931 Long-term Extension From Phase II Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-01","conditions":"Hyperphosphatemia","enrollment":145},{"nctId":"NCT00785629","phase":"NA","title":"A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD","status":"COMPLETED","sponsor":"Denver Nephrologists, P.C.","startDate":"2009-02","conditions":"Chronic Kidney Disease","enrollment":148},{"nctId":"NCT01357317","phase":"PHASE3","title":"Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction","status":"UNKNOWN","sponsor":"Salem Veterans Affairs Medical Center","startDate":"2011-06","conditions":"Chronic Kidney Disease","enrollment":120},{"nctId":"NCT01514851","phase":"PHASE3","title":"Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-01","conditions":"Hyperphosphatemia","enrollment":259},{"nctId":"NCT01116947","phase":"NA","title":"Fosrenol for Enhancing Dietary Protein Intake in Hypoalbuminemic Dialysis Patients (FrEDI) Study","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2010-07","conditions":"End-Stage Renal Disease","enrollment":108},{"nctId":"NCT00438932","phase":"NA","title":"Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2007-01","conditions":"Chronic Kidney Disease","enrollment":16},{"nctId":"NCT00841126","phase":"PHASE3","title":"Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate","status":"TERMINATED","sponsor":"Ineos Healthcare Limited","startDate":"2009-07","conditions":"Chronic Kidney Failure","enrollment":657}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"DIARRHOEA"},{"count":3,"reaction":"NAUSEA"},{"count":2,"reaction":"GASTROINTESTINAL DISORDER"},{"count":2,"reaction":"RENAL DISORDER"},{"count":2,"reaction":"UNRESPONSIVE TO STIMULI"},{"count":2,"reaction":"VOMITING"},{"count":1,"reaction":"ABDOMINAL PAIN"},{"count":1,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"ANAPHYLACTIC REACTION"},{"count":1,"reaction":"ANTI-ERYTHROPOIETIN ANTIBODY POSITIVE"}],"_approvalHistory":[],"publicationCount":537,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FOSRENOL"],"phase":"phase_3","status":"active","brandName":"Fosrenol (Lanthanum Carbonate)","genericName":"Fosrenol (Lanthanum Carbonate)","companyName":"Shire","companyId":"shire","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lanthanum carbonate binds to phosphate in the gastrointestinal tract, forming insoluble complexes that are eliminated in feces, thereby reducing serum phosphate levels. Used for Hyperphosphatemia in patients with chronic kidney disease on dialysis, Hyperphosphatemia in patients with chronic kidney disease not on dialysis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}